Recap: ADMA Biologics Q4 Earnings
Portfolio Pulse from Benzinga Insights
ADMA Biologics (NASDAQ:ADMA) reported Q4 earnings with an EPS of $0.04, doubling the estimated $0.02 and marking a significant revenue increase of $23.92 million from the previous year. This follows a trend of beating EPS estimates and subsequent share price increases.
February 28, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics reported a significant beat on Q4 earnings and a substantial year-over-year revenue increase, continuing its trend of surpassing EPS estimates.
ADMA Biologics' Q4 earnings beat and revenue increase are likely to positively impact investor sentiment and stock price in the short term, continuing its trend of post-earnings share price increases.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100